Rankings
▼
Calendar
WGS
GeneDx Holdings Corp.
$3B
Q3 2024 Earnings
Healthcare
Medical - Healthcare Information Services
Income Statement
Revenue
$77M
+44.2% YoY
Gross Profit
$48M
62.2% margin
Operating Income
-$8M
-10.1% margin
Net Income
-$8M
-10.8% margin
EPS (Diluted)
$-0.31
QoQ Revenue Growth
+9.0%
Cash Flow
Operating Cash Flow
-$4M
Free Cash Flow
-$5M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$409M
Total Liabilities
$204M
Stockholders' Equity
$205M
Cash & Equivalents
$58M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$77M
$53M
+44.2%
Gross Profit
$48M
$25M
+89.4%
Operating Income
-$8M
-$43M
+81.9%
Net Income
-$8M
-$42M
+80.3%
Revenue Segments
Diagnostic Test
$77M
50%
Diagnostic Test, Third Party Insurance
$60M
38%
Diagnostic Test, Institutional Customers
$17M
11%
Diagnostic Test, Self Pay
$460,000
0%
← FY 2024
All Quarters
Q4 2024 →
WGS Q3 2024 Earnings — GeneDx Holdings Corp. Revenue & Financial Results | Market Cap Arena